Biotech · Private company · Cambridge, MA, US
Omega Therapeutics, Inc.
SEC CIK 0001850838
Track this companyFree. Adds Omega Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials10 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- Checkpoint Inhibitor, ImmunePhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- OTX-2002Phase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Tyrosine kinase inhibitor OnePhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Tyrosine kinase inhibitor TwoPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC OncogenePHASE1_PHASE2 · TERMINATED · started Aug 19, 2022ClinicalTrials.gov NCT05497453 · fetched Nov 12, 2026
SEC filings10
- 8-K · 8-KSEC EDGAR · filed Feb 24, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 14, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 3, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 28, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 17, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 10, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 31, 2024 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 6, 2024 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 14, 2024 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 14, 2024 · fetched Nov 12, 2026